We previously reported a relationship between PSADT and MFS in BRPC post RP (Pound 1999; Freedland 2007; Antonarakis 2012). In men with PSADT
In the CPDR/JHU RP database (31,296), 513 men with BCR (>0.2ng/ml) with PSADT
M+ occurred in 218 of 513 patients with BRPC (median follow up 9 years). Risk of M+ increased for PSADT 6.0-7.5, 4.5-6, 3.0-4.5, and ≤3.0 months, adjusted for pT stage and Gleason score. PP ≥ 10 ng/ml significantly increased risk of M+ in pts with PSADT
In men with PSADT
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.